Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial

JL. Bennett, O. Aktas, WA. Rees, MA. Smith, M. Gunsior, L. Yan, D. She, D. Cimbora, SJ. Pittock, BG. Weinshenker, F. Paul, R. Marignier, D. Wingerchuk, G. Cutter, A. Green, HP. Hartung, HJ. Kim, K. Fujihara, M. Levy, E. Katz, BAC. Cree,...

. 2022 ; 86 (-) : 104321. [pub] 20221110

Language English Country Netherlands

Document type Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase II, Clinical Trial, Phase III, Journal Article

Persistent link   https://www.medvik.cz/link/bmc22032328

BACKGROUND: Inebilizumab is an anti-CD19 antibody approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults with aquaporin-4 autoantibodies. The relationship between B-cell, plasma-cell (PC), and immunoglobulin depletion with longitudinal reductions in NMOSD activity after inebilizumab treatment was characterised post hoc in an exploratory analysis from the N-MOmentum study (NCT02200770). METHODS: Peripheral blood CD20+ B cells, PC gene signature, and immunoglobulin levels were assessed throughout N-MOmentum (follow-up ≥2.5 years); correlations with clinical metrics and magnetic resonance imaging (MRI) lesion activity were assessed. FINDINGS: Inebilizumab induced durable B-cell and PC depletion within 1 week versus placebo. Although no association was observed between B-cell counts at time of attack and NMOSD activity, depth of B-cell depletion after the first dosing period correlated with clinical outcomes. All participants receiving inebilizumab demonstrated a robust long-term therapeutic response, and participants with ≤4 cells/μL after the first 6-month dosing interval had persistently deeper B-cell depletion, lower annualised attack rates (estimated rate [95% CI]: 0.034 [0.024-0.04] vs 0.086 [0.056-0.12]; p = 0.045), fewer new/enlarging T2 MRI lesions (0.49 [0.43-0.56] vs 1.36 [1.12-1.61]; p < 0.0001), and a trend towards decreased Expanded Disability Status Scale worsening (0.076 [0.06-0.10] vs 0.14 [0.10-0.18]; p = 0.093). Antibodies to inebilizumab, although present in a proportion of treated participants, did not alter outcomes. INTERPRETATION: This analysis suggests that compared with placebo, inebilizumab can provide specific, rapid, and durable depletion of B cells in participants with NMOSD. Although deep and persistent CD20+ B-cell depletion correlates with long-term clinical stability, early, deep B-cell depletion correlates with improved disease activity metrics in the first 2 years. FUNDING: Horizon Therapeutics (formerly from Viela Bio/MedImmune).

Brain and Mind Centre University of Sydney Sydney NSW Australia

Department of Multiple Sclerosis Therapeutics Fukushima Medical University and Multiple Sclerosis and Neuromyelitis Optica Center Southern Tohoku Research Institute for Neuroscience Koriyama Japan

Department of Neurology Massachusetts General Hospital and Harvard Medical School Boston MA USA

Department of Neurology Mayo Clinic Scottsdale AZ USA

Department of Neurology Medical University Vienna Vienna Austria

Department of Neurology Palacky University in Olomouc Olomouc Czech Republic

Department of Neurology Research Institute and Hospital of National Cancer Center Goyang South Korea

Experimental and Clinical Research Center Max Delbrück Center for Molecular Medicine and Charité Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin Berlin Germany

Horizon Therapeutics plc Gaithersburg MD USA

Mayo Clinic and Center for MS and Autoimmune Neurology Rochester MN USA

Mayo Clinic Rochester MN USA

Medical Faculty Heinrich Heine University Düsseldorf Düsseldorf Germany

Service de Neurologie Sclérose en Plaques Pathologies de la Myéline et Neuroinflammation Hôpital Neurologique Pierre Wertheimer Hospices Civils de Lyon Lyon France

UCSF Weill Institute for Neurosciences Department of Neurology and Department of Ophthalmology University of California San Francisco San Francisco CA USA

UCSF Weill Institute for Neurosciences Department of Neurology University of California San Francisco San Francisco CA USA

University of Alabama at Birmingham Birmingham AL USA

University of Colorado School of Medicine Anschutz Medical Campus University of Colorado Aurora CO USA

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22032328
003      
CZ-PrNML
005      
20230131151838.0
007      
ta
008      
230120s2022 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ebiom.2022.104321 $2 doi
035    __
$a (PubMed)36370634
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Bennett, Jeffrey L $u University of Colorado School of Medicine, Anschutz Medical Campus, University of Colorado, Aurora, CO, USA. Electronic address: jeffrey.bennett@cuanschutz.edu
245    10
$a Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial / $c JL. Bennett, O. Aktas, WA. Rees, MA. Smith, M. Gunsior, L. Yan, D. She, D. Cimbora, SJ. Pittock, BG. Weinshenker, F. Paul, R. Marignier, D. Wingerchuk, G. Cutter, A. Green, HP. Hartung, HJ. Kim, K. Fujihara, M. Levy, E. Katz, BAC. Cree, N-MOmentum study investigators
520    9_
$a BACKGROUND: Inebilizumab is an anti-CD19 antibody approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults with aquaporin-4 autoantibodies. The relationship between B-cell, plasma-cell (PC), and immunoglobulin depletion with longitudinal reductions in NMOSD activity after inebilizumab treatment was characterised post hoc in an exploratory analysis from the N-MOmentum study (NCT02200770). METHODS: Peripheral blood CD20+ B cells, PC gene signature, and immunoglobulin levels were assessed throughout N-MOmentum (follow-up ≥2.5 years); correlations with clinical metrics and magnetic resonance imaging (MRI) lesion activity were assessed. FINDINGS: Inebilizumab induced durable B-cell and PC depletion within 1 week versus placebo. Although no association was observed between B-cell counts at time of attack and NMOSD activity, depth of B-cell depletion after the first dosing period correlated with clinical outcomes. All participants receiving inebilizumab demonstrated a robust long-term therapeutic response, and participants with ≤4 cells/μL after the first 6-month dosing interval had persistently deeper B-cell depletion, lower annualised attack rates (estimated rate [95% CI]: 0.034 [0.024-0.04] vs 0.086 [0.056-0.12]; p = 0.045), fewer new/enlarging T2 MRI lesions (0.49 [0.43-0.56] vs 1.36 [1.12-1.61]; p < 0.0001), and a trend towards decreased Expanded Disability Status Scale worsening (0.076 [0.06-0.10] vs 0.14 [0.10-0.18]; p = 0.093). Antibodies to inebilizumab, although present in a proportion of treated participants, did not alter outcomes. INTERPRETATION: This analysis suggests that compared with placebo, inebilizumab can provide specific, rapid, and durable depletion of B cells in participants with NMOSD. Although deep and persistent CD20+ B-cell depletion correlates with long-term clinical stability, early, deep B-cell depletion correlates with improved disease activity metrics in the first 2 years. FUNDING: Horizon Therapeutics (formerly from Viela Bio/MedImmune).
650    _2
$a dospělí $7 D000328
650    _2
$a lidé $7 D006801
650    12
$a neuromyelitis optica $x farmakoterapie $x patologie $7 D009471
650    _2
$a B-lymfocyty $7 D001402
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a antigeny CD19 $7 D018941
650    _2
$a magnetická rezonanční tomografie $7 D008279
650    _2
$a autoprotilátky $7 D001323
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a multicentrická studie $7 D016448
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
700    1_
$a Aktas, Orhan $u Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
700    1_
$a Rees, William A $u Horizon Therapeutics plc, Gaithersburg, MD, USA
700    1_
$a Smith, Michael A $u Horizon Therapeutics plc, Gaithersburg, MD, USA
700    1_
$a Gunsior, Michele $u Horizon Therapeutics plc, Gaithersburg, MD, USA
700    1_
$a Yan, Li $u Horizon Therapeutics plc, Gaithersburg, MD, USA
700    1_
$a She, Dewei $u Horizon Therapeutics plc, Gaithersburg, MD, USA
700    1_
$a Cimbora, Daniel $u Horizon Therapeutics plc, Gaithersburg, MD, USA
700    1_
$a Pittock, Sean J $u Mayo Clinic and Center for MS and Autoimmune Neurology, Rochester, MN, USA
700    1_
$a Weinshenker, Brian G $u Mayo Clinic, Rochester, MN, USA
700    1_
$a Paul, Friedemann $u Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
700    1_
$a Marignier, Romain $u Service de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuroinflammation, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon, France
700    1_
$a Wingerchuk, Dean $u Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA
700    1_
$a Cutter, Gary $u University of Alabama at Birmingham, Birmingham, AL, USA
700    1_
$a Green, Ari $u UCSF Weill Institute for Neurosciences, Department of Neurology and Department of Ophthalmology, University of California San Francisco, San Francisco, CA, USA
700    1_
$a Hartung, Hans-Peter $u Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany; Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia; Department of Neurology, Medical University Vienna, Vienna, Austria; Department of Neurology, Palacky University in Olomouc, Olomouc, Czech Republic
700    1_
$a Kim, Ho Jin $u Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, South Korea
700    1_
$a Fujihara, Kazuo $u Department of Multiple Sclerosis Therapeutics, Fukushima Medical University and Multiple Sclerosis and Neuromyelitis Optica Center, Southern Tohoku Research Institute for Neuroscience, Koriyama, Japan
700    1_
$a Levy, Michael $u Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
700    1_
$a Katz, Eliezer $u Horizon Therapeutics plc, Gaithersburg, MD, USA
700    1_
$a Cree, Bruce A C $u UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA
710    2_
$a N-MOmentum study investigators
773    0_
$w MED00190061 $t EBioMedicine $x 2352-3964 $g Roč. 86, č. - (2022), s. 104321
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36370634 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20230131151834 $b ABA008
999    __
$a ok $b bmc $g 1891215 $s 1183663
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 86 $c - $d 104321 $e 20221110 $i 2352-3964 $m EBioMedicine $n EBioMedicine $x MED00190061
LZP    __
$a Pubmed-20230120

Find record

Citation metrics

Archiving options